Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 1 | 13 | 12 | — | 27 |
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | 5 | 10 | 2 | — | 17 |
Hyperplasia | D006965 | EFO_0000536 | — | 1 | 5 | 10 | 2 | — | 17 |
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | 4 | 1 | 1 | 9 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 1 | 4 | 1 | — | 5 |
Pulmonary arterial hypertension | D000081029 | — | — | 1 | 1 | 2 | 1 | 1 | 5 |
Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 1 | — | 1 | 1 | 3 |
Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | — | 1 | — | 2 |
Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | 1 | — | 1 |
Vomiting | D014839 | — | R11.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | — | 1 | — | — | 1 |
Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | — | 1 | — | — | 1 |
Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | 1 | — | — | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | — | 1 |
Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Essential hypertension | D000075222 | — | I10 | — | 1 | — | — | — | 1 |
Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
Priapism | D011317 | — | N48.3 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ischemic optic neuropathy | D018917 | EFO_1000809 | H47.01 | — | — | — | — | 1 | 1 |
Optic nerve diseases | D009901 | EFO_1001330 | H47.14 | — | — | — | — | 1 | 1 |
Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | — | 1 | 1 |
Drug common name | Tadalafil |
INN | tadalafil |
Description | Tadalafil is a pyrazinopyridoindole that is 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione substituted at position 2 by a methyl group and at position 6 by a 1,3-benzodioxol-5-yl group (the 6R,12aR-diastereomer). A phosphodiesterase V inhibitor inhibitor, currently marketed in pill form for treating erectile dysfunction under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension. It has a role as an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor and a vasodilator agent. It is a pyrazinopyridoindole and a member of benzodioxoles. |
Classification | Small molecule |
Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O |
PDB | — |
CAS-ID | 171596-29-5 |
RxCUI | — |
ChEMBL ID | CHEMBL779 |
ChEBI ID | 71940 |
PubChem CID | 110635 |
DrugBank | DB00820 |
UNII ID | 742SXX0ICT (ChemIDplus, GSRS) |